At this time, there are no generic versions of Tradjenta (linagliptin) available, as the drug is protected by patents. The first patent is scheduled to expire on April 24, 2017, which would be the earliest date that a generic version of the drug could become available. However, new patents, lawsuits, or other circumstances may come up that could delay the availability of generic Tradjenta.
Tradjenta™ (linagliptin) is a prescription medication approved for treating type 2 diabetes. It belongs to a relatively new class of diabetes medications known as dipeptidyl peptidase-4 (DPP-4) inhibitors. Tradjenta can be used alone or in combination with other diabetes medications.
Tradjenta is marketed by Boehringer Ingelheim Pharmaceuticals, Inc., and Eli Lilly and Company. At this time, generic Tradjenta is not available.
The first patent for Tradjenta is set to expire in April 2017. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to extend or shorten this exclusivity period. This could include such things as lawsuits or other patents for new Tradjenta uses. Once the patent expires, there may be several companies that manufacture a generic Tradjenta drug.
No -- linagliptin is the active ingredient in Tradjenta, but is not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent, and another company besides the original manufacturer must make the product.